paclobutrazol
Commercial- Indications
- Plant growth regulation
Company intelligence / Profile preview
Peptech Limited
Macquarie Park/Sydney*, New South Wales, Australiapeptechcorp.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
PMX53, a potent orally bioavailable C5a antagonist developed by Promics Pty and acquired by Peptech Limited, completed Phase I safety testing. The company intended to advance PMX53 into Phase II trials for inflammatory and autoimmune indications following additional formulation studies.
- Therapeutic areas
- PulmonologyCardiovascularImmunology
- Modalities
- Small moleculePeptides
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of Queensland/Promics Pty Ltd.BioVentures Australia
Beyond the preview
Go deeper on Peptech Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peptech Limited.